$97.5 Million is the total value of Stonepine Capital Management, LLC's 23 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
BDSI | Exit | BioDelivery Sciences International, Inc. | $0 | – | -8,523 | -100.0% | -0.03% | – |
INSYQ | Exit | INSYS Therapeutics, Inc. | $0 | – | -2,000 | -100.0% | -0.04% | – |
ANIP | Exit | ANI Pharmaceuticals, Inc. | $0 | – | -1,650 | -100.0% | -0.07% | – |
RPTP | Exit | Raptor Pharmaceuticals Corp. | $0 | – | -20,000 | -100.0% | -0.11% | – |
ZLTQ | Exit | ZELTIQ Aesthetics, Inc. | $0 | – | -70,000 | -100.0% | -2.24% | – |
CTIC | Exit | CTI BIOPHARMA CORP | $0 | – | -3,743,340 | -100.0% | -2.35% | – |
Exit | PERNIX THERAPEUTICS HOLDINGSdebt | $0 | – | -6,000,000 | -100.0% | -2.73% | – | |
PTX | Exit | PERNIX THERAPEUTICS HOLDINGS | $0 | – | -3,215,861 | -100.0% | -3.98% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2016-08-11
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
CTI Biopharmap Corp. | 24 | Q1 2023 | 14.8% |
APOLLO ENDOSURGERY INC | 23 | Q1 2023 | 15.6% |
XOMA CORP | 20 | Q3 2023 | 5.7% |
Cumberland Pharmaceuticals, Inc. | 19 | Q4 2020 | 7.0% |
Amarin Corp PLC - SPONS ADR | 14 | Q3 2022 | 23.2% |
VANDA PHARMACEUTICALS INC | 14 | Q3 2023 | 20.9% |
BIODELIVERY SCIENCES INTL | 14 | Q1 2020 | 12.9% |
AFFIMED NV | 13 | Q3 2022 | 7.7% |
ALIMERA SCIENCES INC | 13 | Q3 2019 | 4.2% |
VIVEVE MEDICAL INC | 12 | Q2 2019 | 15.3% |
View Stonepine Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
CTI BIOPHARMA CORP | April 13, 2023 | 7,018,046 | 5.3% |
ADMA BIOLOGICS, INC. | February 13, 2023 | 6,940,000 | 3.1% |
Amryt Pharma plc | February 13, 2023 | 31,666,195 | 9.9% |
Apollo Endosurgery, Inc. | February 13, 2023 | 4,351,088 | 9.0% |
Conformis Inc | February 13, 2023 | 748,194 | 9.9% |
Ovid Therapeutics Inc.Sold out | February 13, 2023 | 0 | 0.0% |
Adamas Pharmaceuticals IncSold out | February 14, 2022 | 0 | 0.0% |
CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
Conformis Inc | February 14, 2022 | 14,768,823 | 7.9% |
YUMANITY THERAPEUTICS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Stonepine Capital Management, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
SC 13G | 2024-04-19 |
13F-HR | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
View Stonepine Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.